Cite
HARVARD Citation
Maughan, B. et al. (2021). Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist. pp. 1006-e2129. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Maughan, B. et al. (2021). Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist. pp. 1006-e2129. [Online].